Neurocrine biosciences presents cahtalyst™ adult study baseline characteristics and data on impact of supraphysiologic glucocorticoid therapy at aace 2024

Cahtalyst™ study baseline characteristics highlight the need for new treatment options to reduce adrenal androgens and supraphysiologic glucocorticoid dosing in cah adult patients comprehensive literature review identified potential psychological and cognitive impact of high glucocorticoid doses in cah patients san diego , may 9, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced that it will present cahtalyst™ adult phase 3 clinical study baseline characteristics for adults with congenital adrenal hyperplasia (cah) enrolled in the study, as well as data from a comprehensive literature review assessing the impact of supraphysiologic glucocorticoid (gc) doses on psychiatric disorders and cognition in patients with cah. the cahtalyst adult study baseline data demonstrate the potential long-term consequences of current cah treatments, with many patients in young adulthood experiencing disorders found more commonly in people decades older, including osteopenia, hypertension and hyperlipidemia.
NBIX Ratings Summary
NBIX Quant Ranking